As teamLab Planets in Tokyo Welcomes Around 1 Million Visitors From Abroad in a 6-Month Period, the Immersive Museum Unveils the Renewal of Artwork Spaces
31.8.2023 19:00:00 EEST | Business Wire | Press release
teamLab Planets TOKYO DMM ("teamLab Planets"), the body-immersive museum by art collective teamLab in Toyosu, Tokyo, celebrated its fifth anniversary with the renewal of artwork spaces, making it an even more immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830716639/en/
As visitors touch the countless crystals of light floating in the air, the work transforms interactively. On view at teamLab Planets, a body immersive museum in Toyosu, Tokyo. (teamLab, Ephemeral Solidified Light / Photo: teamLab)
In the six months from March to August 2023, the museum has received approximately one million visitors from 182 countries and regions outside of Japan. This makes up 70% of the museum’s total number of visitors (*1). It has also been reported that approximately 1 in 10 visitors to Japan from overseas are visiting teamLab Planets (*2).
NEWLY UNVEILED INSTALLATION: EPHEMERAL SOLIDIFIED LIGHT
Inside an immersive artwork that visitors experience by entering the water, countless masses of light float in the air, each one composed of multiple colors. The boundaries of each color are clearly separated as though they are solid. The seemingly solid color separation of the masses of light is not seen in the natural world, and is caused by extreme synchronization. Through self-organization over time, this synchronization phenomenon creates a large ordered structure.
RENEWAL OF ARTWORK SPACES
In The Infinite Crystal Universe, an artwork that creates a three-dimensional sculpture from a collection of light points, visitors can participate in the work using the teamLab app and create the artwork together with other people in the space. By throwing in a star of your choice from the app, a light sculpture is created in front of you, and the space of this work is created by a group of these light sculptures. With the renewal, five new light sculptures have been added to the installation.
An installation filled with spheres of light that change to ambiguous colors through people’s interactions, Expanding Three-dimensional Existence in Transforming Space, and several other artwork spaces have also been renewed, furthering the experience of physically immersing the entire body.
In addition, teamLab Planets, which was originally scheduled to close at the end of 2023, has been extended to the end of 2027 due to the popularity of the museum.
CONCEPT BEHIND TEAMLAB PLANETS
Together with Others, Immerse your Entire Body, Perceive with your Body, and Become One with the World
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. It comprises 4 large-scale artwork spaces and 2 gardens created by art collective teamLab.
People go barefoot and immerse their entire bodies in the vast artworks together with others. The artworks change under the presence of people, blurring the perception of boundaries between the self and the works. Other people also create change in the artworks, blurring the boundaries between themselves and the works, and creating a continuity between the self, the art, and others.
-----------------------
*1, teamLab Planets Official Website, Ticket Purchasing Data (data obtained from March 1st - Aug 31st, 2023)
*2 “Amazing Nippon / Digital Art Museum in Tokyo Enchants Overseas Tourists - The Japan News” The Japan News by the Yomiuri Shimbun. August 5, 2023.
About the Museum
teamLab Planets TOKYO DMM
6-1-16 Toyosu, Koto-ku, Tokyo
https://www.teamlab.art/e/planets/
Hours
September - November: 09:00 - 22:00
*Last entry 1 hour before closing
*Hours are subject to change. Please check the official website for the latest information.
Closed: September 6th (Wed), October 4th (Wed), November 8th (Wed)
Admission
Adult (18 years and over): 3,800 JPY
Student (13 - 17 years): 2,300 JPY
Child (4 - 12 years): 1,300 JPY
3 years and under: Free
Disability discount: 1,900 JPY
Official Ticket Store
https://teamlabplanets.dmm.com
Food & Shop
Vegan Ramen UZU Tokyo: https://vegan-uzu.com/pages/uzu-tokyo-en
teamLab Flower Shop: https://www.teamlab.art/e/flowershop/
For Media
Press Kit: https://goo.gl/tQXMLm
Highlight Video: https://youtu.be/KAQMAzRjoH0
About PLANETS Co., Ltd.
Established in 2017. Operates and manages the facilities of teamLab Planets TOKYO.
Location: Tokyo Nihonbashi Tower 10F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Takumi Nomoto
About teamLab
teamLab (f. 2001) is an international art collective. Their collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world. Through art, the interdisciplinary group of specialists, including artists, programmers, engineers, CG animators, mathematicians, and architects, aims to explore the relationship between the self and the world, and new forms of perception.
In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perceptions of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.
teamLab exhibitions have been held in cities worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, and Melbourne among others. teamLab museums and large-scale permanent exhibitions include teamLab Borderless and teamLab Planets in Tokyo, teamLab Borderless Shanghai, teamLab SuperNature Macao, and teamLab Massless Beijing, with more to open in cities including Abu Dhabi, Hamburg, Jeddah, and Utrecht.
teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki, among others.
teamLab is represented by Pace Gallery, Martin Browne Contemporary, and Ikkan Art.
teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
Facebook: https://www.facebook.com/teamLab.inc
Twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830716639/en/
Contact information
PLANETS Co., Ltd. Public Relations Department
E-mail: pr-info@planets.art
Interview: https://forms.gle/fAtnDKLpQKFME6XR9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom